Clarivate Plc

What they do

Clarivate provides intelligence, workflow, and tech-enabled services built on proprietary data and analytics, serving over 45,000 customers in Academia & Government, Intellectual Property, and Life Sciences & Healthcare. Its solutions support the innovation lifecycle from research to commercialization, with AI research assistants and agents integrated into its offerings. Revenue comes from subscription, re-occurring (patent/trademark renewals), and transactional sources.

Revenue drivers

• Subscription-based revenues — Annual contracts licensing product access and maintenance; recurring and stable, with organic subscription growth of 0.7% in Q2 2026.
• Re-occurring revenues (patent and trademark renewals) — Services to maintain and protect IP rights globally; recurring in nature, contributing to organic recurring revenue growth of 0.7% in H1 2026.
• Transactional revenues — Project-based sales including content, consulting, and implementation; declined in H1 2026, offsetting recurring growth and leading to negative organic revenue.

Recent performance

In Q2 2026, total revenues were $587.3M, down 5.5% YoY due to inorganic divestitures, with organic revenues declining 1.5%. Net loss widened to $268.6M from $72.0M, driven by a $221.7M goodwill impairment. Adjusted EBITDA was $247.2M (down from $261.6M). H1 2026: revenues $1,172.8M, net loss $308.8M, adjusted EBITDA $488.4M, with $233.4M operating cash flow and $122.9M free cash flow.

Strategy

Management is executing a Value Creation Plan focused on accelerating AI innovation at scale, expanding organic recurring revenue, and disciplined cost management. The company announced the divestiture of its Life Sciences & Healthcare segment to sharpen focus and enhance financial profile, aiming for higher recurring revenue mix and greater financial flexibility. Deleveraging is a priority, with debt reduced by over $200M in H1 2026 through free cash flow and debt repurchases.

Risks

• Third-party data dependence — Substantially all products rely on third-party or public data; renewals or renegotiations could lead to price increases, unfavorable terms, or loss of sole-source feeds.
• Competition from free information sources — Increased access to free or inexpensive information could reduce demand for Clarivate's paid content and services.
• AI technology and regulation — Rapid AI changes, regulatory shifts, or failure to keep pace could adversely affect product adoption and market position.
• Budget cuts and funding reductions — Reductions in customers' research budgets or government funding could lower renewal rates and revenues.

Outlook

Management reaffirmed the full-year 2026 financial outlook, citing resilience and disciplined execution. They expect continued progress toward a subscription-led revenue base, with organic ACV growth of 1.5% in Q2. The Life Sciences & Healthcare divestiture is expected to create a more focused company with improved financial profile, though market risks remain unchanged as of June 30, 2026.